nipah
viru
niv
reemerg
zoonot
pathogen
genu
henipaviru
paramyxovirida
famili
virus
niv
endem
bangladesh
malaysia
highli
fatal
livestock
human
human
case
fatal
rate
current
approv
vaccin
niv
market
goal
studi
use
recombin
rabv
vector
express
niv
glycoprotein
niv
g
develop
bival
candid
vaccin
niv
diseas
rabi
viru
rabv
diseas
also
signific
health
burden
region
niv
endem
rabi
vector
wellestablish
vaccin
strain
lack
neurovirul
stabli
express
foreign
antigen
immunogen
variou
anim
model
mice
inocul
intranas
live
recombin
rabvniv
vaccin
niparab
show
sign
diseas
test
immunogen
vaccin
candid
group
mice
immun
intramuscularli
singl
dose
live
vaccin
particl
two
dose
chemic
inactiv
viral
particl
vaccin
group
show
niv
gspecif
seroconvers
inactiv
inac
vaccin
group
yield
higher
titer
niv
gspecif
antibodi
furthermor
crossreact
niv
gspecif
immun
sera
hendra
viru
hev
confirm
immunofluoresc
indirect
elisa
solubl
recombin
hev
glycoprotein
hev
g
live
kill
vaccin
induc
neutral
antibodi
result
indic
niparab
may
use
kill
viru
vaccin
protect
human
niv
rabv
possibl
prevent
measur
hev
well
npj
vaccin
http
doi
nipah
diseas
highli
fatal
zoonot
diseas
whose
caus
agent
nipah
viru
neg
sens
rna
viru
henipaviru
genu
within
paramyxovirida
famili
niv
discov
outbreak
enceph
malaysia
identifi
isol
method
japanes
enceph
prevent
ineffect
inaugur
niv
outbreak
caus
least
case
enceph
death
necessit
cull
million
pig
found
import
transmiss
human
although
outbreak
malaysia
occur
outbreak
india
nearli
annual
outbreak
bangladesh
sinc
typic
result
battohuman
transmiss
via
consumpt
contamin
raw
date
palm
sap
outbreak
may
state
kerala
india
case
fatal
rate
solidifi
niv
persist
grave
threat
south
asia
infect
fruit
bat
natur
reservoir
viru
seem
asymptomat
howev
pig
suffer
respiratori
neurolog
symptom
infect
human
often
highli
fatal
clinic
manifest
character
fever
headach
visual
motor
skill
dysfunct
acut
respiratori
ill
enceph
niv
strain
caus
human
case
bangladesh
india
produc
greater
respiratori
issu
instanc
humantohuman
transmiss
outbreak
strain
malaysia
case
mark
higher
mortal
rate
reflect
pathogen
differ
strain
well
less
develop
healthcar
infrastructur
region
niv
attach
fusion
entri
requir
coordin
effort
two
membraneanchor
envelop
protein
success
infect
glycoprotein
g
bind
receptor
host
target
cell
fusion
f
protein
respons
drive
fusion
appos
viral
cellular
membran
entri
cellular
receptor
highli
conserv
potenti
host
speci
similar
includ
human
hors
pig
cat
dog
fli
fox
thu
confirm
abil
niv
infect
wide
array
mammalian
speci
niv
g
show
affin
receptor
higher
glycoprotein
close
relat
hendra
viru
hev
known
caus
outbreak
sever
respiratori
diseas
hors
follow
transmiss
human
strong
neurotrop
niv
could
explain
fact
highli
express
nervou
system
niv
classifi
biosafeti
level
pathogen
consid
bioterror
agroterror
threat
safe
effect
vaccin
niv
human
livestock
would
greatli
benefici
prevent
niv
diseas
endem
region
reduc
risk
niv
becom
global
danger
current
work
establish
niv
vaccin
pursu
variou
promis
approach
outlin
liveattenu
recombin
measl
viru
mv
express
niv
g
human
use
rmvedg
complet
protect
hamster
upon
lethal
niv
challeng
followup
studi
two
african
green
monkey
agm
immun
dose
rmvedg
subsequ
challeng
clinic
sign
euthanasia
mvbase
vaccin
vector
confer
longlast
immun
furthermor
preexist
immun
mv
human
popul
seem
confound
success
vaccin
attempt
vlpbase
vaccin
approach
also
test
efficaci
syrian
golden
hamster
challeng
model
vlp
antigen
similar
parent
viru
gener
immunogen
subunit
vaccin
stimul
humor
cellular
arm
immun
system
singl
tripl
dose
vlp
express
niv
g
abl
fulli
protect
hamster
challeng
adjuv
requir
boost
immun
achiev
high
titer
neutral
antibodi
nab
moreov
incomplet
lethal
model
allow
surviv
control
group
receiv
vaccin
therebi
complic
vaccinespecif
effect
surviv
test
preclin
model
warrant
singl
administr
liveattenu
replicationcompet
recombin
vesicular
stomat
viru
vsv
lack
nativ
glycoprotein
express
ebola
gp
niv
g
rvsvzebovgpnivg
shown
prevent
viru
shed
replic
nipah
diseas
agm
live
vsvbase
vaccin
vector
may
util
emerg
situat
ring
vaccin
regulatori
approv
use
human
slow
due
concern
regard
potenti
pathogenesi
widespread
advers
event
question
efficaci
human
popul
rvsvebov
may
repres
exist
gap
vsvvector
vaccin
approach
howev
replicationdefect
singlecycl
recombin
vesicular
stomat
virus
pseudotyp
either
niv
f
g
show
protect
time
ld
niv
challeng
syrian
golden
hamster
singl
dose
inocul
offer
distinct
safeti
advantag
liveattenu
rvsvzebovgpnivg
nonetheless
product
requir
multipl
plasmid
transfect
costli
largescal
manufactur
studi
aim
develop
rabvbas
vaccin
niv
anim
human
vaccin
base
rabv
shown
induc
strong
humor
respons
pathogen
inactiv
rabv
vaccin
consid
remark
safe
parent
rabv
vector
use
studi
deriv
sad
strain
vaccin
strain
attenu
tissu
cultur
passag
vector
design
contain
addit
rabv
stopstart
transcript
signal
sequenc
uniqu
bsiwi
nhei
restrict
site
nucleoprotein
n
phosphoprotein
p
gene
introduct
foreign
gene
increas
safeti
profil
vector
arginin
glutam
acid
mutat
introduc
amino
acid
posit
rabv
g
greatli
reduc
neurovirul
develop
fulllength
niparab
cdna
use
recoveri
recombin
viru
insert
codonoptim
version
niv
g
bangladesh
strain
vector
rabv
n
p
gene
cdna
serv
antigenom
templat
singlestrand
negativesens
rna
genom
made
recoveri
construct
cotransfect
bsr
cell
along
support
plasmid
individu
bear
rabv
gene
requir
assembl
packag
bud
recombin
virion
previous
describ
studi
gener
live
version
vaccin
chemic
inactiv
version
use
beta
propiolacton
imped
viru
replic
maintain
antigen
target
immunogen
fig
express
niv
g
niparab
success
antigen
niv
g
rabv
g
vaccin
depend
express
surfac
niparabinfect
produc
cell
host
cellderiv
envelop
viral
progeni
contain
glycoprotein
analyz
coexpress
vero
cell
either
mock
infect
infect
live
niparab
multipl
infect
moi
h
perform
surfac
immunofluoresc
assay
follow
confoc
microscopi
imag
cell
dual
stain
human
monoclon
antibodi
direct
rabv
g
either
pool
polyclon
necropsi
sera
mice
immun
dose
inac
niparab
one
intranas
dose
live
recombin
vsv
express
hendra
g
rvsvhevg
hendra
gspecif
sera
use
knowledg
crossreact
identifi
niv
g
express
absenc
niv
gspecif
sera
niparabinfect
cell
coexpress
rabv
g
niv
g
fig
indic
niparab
viabl
bival
vaccin
vector
confirm
rabv
g
niv
g
incorpor
niparab
virion
evalu
purifi
virion
sever
differ
recombin
virus
sdspage
sypro
rubi
stain
fig
promin
band
appar
molecular
size
slightli
kda
exclus
detect
lane
contain
inac
niparab
virion
solubl
niv
g
protein
fig
band
consist
expect
size
niv
g
migrat
similarli
distinctli
lower
hev
g
kda
deriv
virion
recombin
express
codonoptim
hev
g
hendrarab
niparab
virion
also
incorpor
necessari
rabv
protein
determin
comparison
parent
virion
purifi
virion
also
assess
western
blot
probe
rabbit
polyclon
hev
g
antisera
fig
band
correspond
hev
g
kda
niv
g
kda
specif
detect
lane
contain
hendrarab
niparab
viral
particl
respect
furthermor
solubl
recombin
niv
g
protein
transmembran
domain
ntermin
cytoplasm
tail
delet
also
detect
slightli
lower
molecular
size
fulllength
protein
expect
find
consist
result
stain
protein
gel
signifi
specif
sera
hev
g
could
crossreact
niv
g
protein
detect
neg
control
virion
parent
recombin
express
unrel
glycoprotein
marburg
viru
result
indic
niv
g
success
incorpor
rabv
vaccin
vector
niv
g
incorpor
increas
rabv
vaccin
pathogen
incorpor
niv
g
rabv
vector
trigger
safeti
concern
kill
vaccin
could
issu
use
live
viral
vector
niv
neurotrop
sinc
envelop
protein
bind
receptor
predominantli
express
neuron
cell
nipah
diseas
known
caus
enceph
neurolog
symptom
infect
human
therefor
live
niparab
inocul
could
potenti
lead
pathogen
restor
neurovirul
even
though
nonvirul
peripher
administr
adult
mice
studi
potenti
impact
three
group
ten
mice
split
equal
gender
infect
log
focusform
unit
ffu
either
live
neg
control
niparab
spbn
posit
control
anim
monitor
weight
loss
clinic
sign
diseas
day
observ
immedi
latent
advers
effect
endpoint
criteria
euthanasia
weight
loss
exceed
origin
bodi
weight
hallmark
neurolog
symptom
ataxia
spbn
deriv
rabi
viru
vaccin
strain
lack
attenu
mutat
rabv
g
make
lethal
administ
adult
mice
mice
receiv
spbn
succumb
infect
day
postexposur
wherea
mice
inocul
remain
healthi
weight
loss
malais
similarli
mice
infect
live
niparab
surviv
durat
studi
appar
pathogen
indic
steadi
weight
gain
absenc
neurolog
diseas
fig
b
data
demonstr
addit
niv
g
reestablish
pathogen
parent
vector
within
immun
compet
mous
model
may
safe
use
wildlif
vaccin
immunogen
niv
g
analyz
humor
respons
niv
g
elicit
niparab
group
ten
mice
male
femal
intramuscularli
im
immun
one
dose
ffu
live
dose
ug
either
inac
niparab
inac
fig
sera
collect
day
analyz
indirect
elisa
use
solubl
niv
g
captur
antigen
quantit
determin
niv
gspecif
antibodi
titer
posit
control
assay
includ
pool
antisera
group
mice
immun
live
recombin
vsv
express
codonoptim
hev
g
shown
crossreact
toward
niv
g
western
blot
fig
fig
robust
seroconvers
achiev
earli
day
singl
vaccin
group
immun
either
live
inac
niparab
control
group
receiv
inac
fig
approxim
week
complet
primeboost
immun
schedul
day
character
final
sera
elisa
analyz
persist
niv
gspecif
humor
respons
averag
valu
group
calcul
base
logist
regress
curv
anim
mice
vaccin
live
inac
niparab
elicit
substanti
higher
titer
antiniv
g
antibodi
compar
neg
control
anim
display
background
level
reactiv
ie
valu
undetermin
fig
tabl
furthermor
male
femal
mice
immun
inac
niparab
significantli
higher
niv
gspecif
antibodi
titer
either
male
femal
mice
receiv
live
niparab
fig
tabl
group
mice
seroconvert
toward
rabv
g
male
femal
anim
inac
niparab
group
show
significantli
higher
titer
rabv
gspecif
antibodi
either
male
femal
anim
neg
control
live
niparab
group
fig
tabl
previou
studi
lab
rabvvector
vaccin
hemorrhag
fever
virus
discov
antibodi
qualiti
inform
surviv
humor
respons
benefici
control
infect
lethal
challeng
mice
skew
toward
product
antibodi
indic
respons
wherea
gener
antibodi
suggest
immun
assess
rel
titer
antibodi
niv
gspecif
sera
anim
immun
either
live
inac
niparab
isotyp
elisa
wherea
signific
differ
p
titer
vs
antibodi
either
male
femal
mice
receiv
live
niparab
male
femal
mice
receiv
inac
niparab
significantli
higher
titer
vs
fig
tabl
moreov
inac
niparab
mice
significantli
higher
titer
antibodi
compar
live
vaccin
group
regardless
gender
fig
tabl
vaccineinduc
niv
g
neutral
antibodi
titer
neutral
antibodi
nab
correl
protect
mani
envelop
virus
includ
rabv
respiratori
syncyti
viru
dengu
fever
viru
evalu
capac
antibodi
elicit
niparab
vaccin
neutral
niv
employ
vitro
fluoresc
reduct
neutral
assay
perform
describ
materi
method
fig
gray
bar
hevspecif
sera
effect
neutral
niv
henc
demonstr
hev
gspecif
antibodi
bind
niv
g
also
possess
antivir
effector
function
neutral
observ
sera
neg
control
mice
immun
inac
expect
sinc
mice
niv
gspecif
antibodi
titer
elisa
fig
group
howev
sera
mice
immun
inac
niparab
develop
nab
fig
vaccin
construct
schemat
represent
recombin
rabi
viru
attenu
sad
vaccin
strain
genom
express
codonoptim
nipah
viru
glycoprotein
gene
bangladesh
strain
nucleoprotein
n
phosphoprotein
p
gene
rabi
asterisk
indic
mutat
amino
acid
posit
rabv
g
attenu
neurovirul
parent
vector
foreign
gene
insert
use
neg
control
immunogen
pathogen
studi
also
depict
b
confoc
microscopi
imag
vero
cell
ether
mock
infect
infect
moi
h
live
niparab
fix
dual
stain
human
monoclon
antibodi
direct
rabv
g
green
either
polyclon
sera
mice
immun
inac
niparab
pool
sera
day
postinfect
dpi
mice
receiv
dose
live
rvsvhevg
pool
sera
dpi
mice
receiv
one
dose
pfu
red
scale
bar
repres
although
titer
variabl
individu
anim
fig
group
similarli
mice
vaccin
live
niparab
gener
niv
gspecif
nab
except
male
anim
nab
titer
detect
fig
group
account
two
anim
signific
differ
nab
titer
live
niparabimmun
male
correspond
femal
p
well
compar
male
femal
immun
inac
niparab
p
overal
anim
inac
niparab
cohort
significantli
higher
titer
nab
anim
correspond
live
vaccin
group
p
result
suggest
neutral
may
import
compon
vaccineinduc
protect
niparab
dose
kill
vaccin
immunogen
inocul
live
vaccin
regard
gener
nivspecif
nab
howev
challeng
studi
anim
vaccin
niparab
need
conduct
determin
nab
correl
surviv
nipah
viru
one
eight
virus
design
world
health
organ
prioriti
pathogen
due
potenti
caus
intern
epidem
absenc
effect
drug
vaccin
although
outbreak
sporad
mortal
rate
human
high
furthermor
signific
econom
burden
pig
farmer
endem
region
whose
livestock
must
cull
respons
outbreak
describ
develop
kill
recombin
rabiesvector
niv
vaccin
niparab
eventu
use
human
prevent
niv
diseas
also
character
live
attenu
niparab
vaccin
consid
use
wildlif
curb
transmiss
natur
reservoir
pteropid
bat
secondari
reservoir
eg
pig
diminish
spillov
event
human
base
studi
african
green
monkey
agm
compar
pathogen
differ
malaysian
niv
bangladesh
niv
b
strain
niv
ident
experiment
condit
decid
choos
niv
b
immunogen
candid
niparab
vaccin
niv
b
caus
mortal
infect
agm
niv
caus
mortal
furthermor
histopatholog
niv
b
infect
agm
show
sever
lung
spleen
phenotyp
shorter
therapeut
window
human
monoclon
antibodi
treatment
niv
infect
counterpart
sinc
amino
acid
sequenc
homolog
glycoprotein
two
strain
effect
vaccin
highli
pathogen
niv
b
strain
would
like
protect
exposur
niv
fact
demonstr
experiment
ferret
vaccin
live
attenu
vesicular
stomat
viru
vsv
vaccin
express
niv
g
bangladesh
strain
protect
heterolog
challeng
malaysian
isol
niv
studi
also
success
util
f
protein
niv
develop
protect
vaccin
strain
hev
decid
target
glycoprotein
block
virionreceptor
bind
entri
step
occur
membran
fusion
result
indic
live
inactiv
niparab
elicit
strong
humor
immun
mice
character
high
titer
antibodi
niv
g
fig
induct
potent
neutral
antibodi
wildtyp
malaysian
niv
strain
fig
antibodi
gener
inac
niparab
mainli
isotyp
suggest
respons
antivir
defens
antibodi
known
particip
nonneutr
effector
function
nk
cellmedi
antibodi
depend
cytotox
adcc
macrophagemonocytemedi
antibodi
depend
cellular
phagocytosi
adcp
possibl
mechan
contribut
vaccineinduc
protect
inac
niparab
addit
classic
neutral
inac
niparab
offer
sever
advantag
niv
vaccin
current
develop
sinc
candid
vaccin
human
chemic
kill
viral
replic
complet
abrog
render
vaccin
potenti
safer
niv
vaccin
use
live
vector
eg
liveattenu
rvsvzebovgpniv
g
especi
suscept
popul
like
immunocompromis
individu
pregnant
women
children
live
viru
vaccin
might
better
intend
use
wildlif
inde
rabi
strain
upon
recombin
niparab
base
sad
success
use
live
oral
vaccin
wildlif
europ
data
shown
live
niparab
caus
pathogen
mice
even
administ
high
dose
ffu
intranas
ad
benefit
bival
toward
rabi
devast
pathogen
wide
affect
human
wildlif
geograph
region
niv
outbreak
occur
moreov
inac
niparab
immunogen
singl
dose
unadjuv
vaccin
fig
titer
remain
elev
even
one
month
secondari
unadjuv
immun
contrast
solubl
niv
hev
glycoprotein
subunit
vlpbase
vaccin
requir
one
dose
adjuv
immunogen
furthermor
inac
niparab
contend
issu
preexist
vector
immun
human
cohort
like
measlesvector
niv
vaccin
previou
studi
shown
addit
immun
subsequ
vaccin
rabiesvector
inactiv
vaccin
studi
describ
demonstr
potenti
rabv
platform
develop
safe
effect
niv
vaccin
futur
studi
test
niparab
protect
anim
model
suscept
niv
syrian
golden
hamster
also
establish
minimum
protect
dose
capac
reduc
niv
diseas
sever
andor
mortal
furthermor
protect
hev
challeng
assess
sinc
wide
evid
sera
cross
reactiv
two
henipavirus
insert
codonoptim
nipah
viru
glycoprotein
gene
g
bangladesh
strain
genbank
n
p
gene
parent
rabi
vector
use
bsiwi
nhei
restrict
site
codon
bia
optim
human
codon
use
carri
genscript
inc
result
plasmid
design
niparab
correct
sequenc
plasmid
confirm
sequenc
use
primer
target
region
n
p
gene
fig
pathogen
live
niparab
vaccin
male
femal
mice
group
ten
mice
male
femal
per
group
intranas
infect
ffu
live
recombin
virus
niparab
neg
control
spbn
posit
control
mice
weigh
daili
monitor
sign
diseas
day
postinocul
endpoint
criteria
euthanasia
reach
mice
lost
origin
bodi
weight
display
symptom
diseas
weight
curv
report
percentag
lost
gain
time
baselin
weight
b
surviv
curv
mice
studi
logrank
mantelcox
test
use
comparison
surviv
curv
assess
signific
differ
surviv
recoveri
recombin
vector
xtremegen
transfect
reagent
roch
diagnost
optimem
use
transfect
fulllength
viral
cdna
clone
along
support
plasmid
bear
rabv
n
p
g
l
gene
control
promot
plasmid
express
rna
polymeras
bsr
cell
plate
describ
previous
success
recoveri
determin
rabi
focusform
assay
briefli
seven
day
transfect
supernat
transfect
well
plate
transfer
duplic
well
plate
seed
vero
cell
fortyeight
hour
later
cell
plate
fix
aceton
stain
fitcconjug
antibodi
rabv
n
fujirebio
diagnost
inc
fluoresc
microscopi
use
observ
appear
viral
foci
indic
recov
infecti
recombin
rabv
niparab
grown
largescal
infect
vero
cell
plate
moi
supernat
collect
everi
day
harvest
harvest
titer
use
rabi
focusform
assay
harvest
pool
concentr
stir
ultrafiltr
cell
millipor
concentr
supernat
centrifug
h
sucros
cushion
use
ti
rotor
beckman
inc
pellet
viru
particl
virion
pellet
resuspend
phosphatebuff
salin
pb
protein
concentr
determin
use
bicinchonin
acid
bca
assay
kit
pierc
viru
particl
chemic
inactiv
bpl
dilut
overnight
bpl
viru
prepar
inactiv
next
day
hydrolysi
min
absenc
infecti
particl
verifi
inocul
vero
cell
vessel
bplinactiv
viru
two
passag
inocul
cell
fix
stain
fitcconjug
antirabv
n
mab
visual
fluoresc
microscopi
presenc
foci
infect
immunofluoresc
test
vaccin
vero
cell
plate
onto
well
plate
cell
mm
circular
diamet
coverslip
insert
incub
overnight
next
day
well
infect
moi
serumfre
media
optipro
per
well
niparab
mix
rock
store
h
h
cell
wash
ml
pb
fix
paraformaldehyd
pfa
dilut
pb
min
room
temperatur
pfa
fig
analysi
termin
sera
niparab
immun
mice
b
averag
valu
bar
deriv
elisa
curv
measur
either
total
niv
g
igg
left
panel
rabv
g
middl
panel
individu
mice
open
circl
vaccin
group
statist
signific
perform
use
anova
follow
uncorrect
fisher
lsd
compar
immun
group
p
p
p
p
c
isotyp
respons
final
sera
day
live
inactiv
niparabimmun
mice
assess
elisa
day
averag
valu
bar
determin
base
individu
elisa
curv
open
circl
statist
signific
perform
use
anova
follow
uncorrect
fisher
lsd
test
compar
immun
group
p
p
p
p
error
bar
repres
standard
deviat
mean
three
replic
valu
ii
immun
three
group
mice
immun
intramuscularli
viru
particl
total
volum
per
hindlimb
three
group
follow
inactiv
niparab
live
niparab
inactiv
group
consist
male
femal
mice
mice
receiv
inactiv
vaccin
given
two
dose
day
day
mice
receiv
live
niparab
vaccin
immun
day
iii
pathogen
experi
three
group
mice
intranas
infect
ffu
live
viru
spbn
niparab
group
consist
male
femal
mice
mice
monitor
sign
diseas
ruffl
fur
ataxia
disorient
weigh
day
mice
lost
origin
weight
consid
reach
endpoint
euthan
product
hatag
niv
g
subconflu
flask
cell
human
kidney
cell
line
transfect
eukaryot
express
vector
pdisplay
encod
amino
acid
head
stalk
domain
codonoptim
niv
g
bangladesh
strain
fuse
ntermin
hemagglutinin
ha
peptid
supernat
collect
h
transfect
clarifi
centrifug
filter
filter
load
onto
equilibr
antiha
agaros
column
pierc
contain
ml
agaros
bed
volum
supernat
allow
bind
column
overnight
next
day
column
wash
volum
tbst
tb
tween
volum
tb
bound
haconivg
elut
ml
ha
peptid
tb
fraction
collect
analyz
presenc
haconivg
western
blot
monoclon
antiha
antibodi
sigma
prepar
bsatbst
peak
fraction
pool
dialyz
pb
molecular
weight
cutoff
dialysi
cassett
mwco
thermo
scientif
remov
excess
ha
peptid
dialysi
protein
quantifi
bca
frozen
aliquot
rabv
niv
g
respons
elisa
sera
immun
mice
collect
retroorbit
eye
bleed
isofluran
anesthesia
day
sampl
test
immunogen
indirect
elisa
use
nterminu
hatag
solubl
recombin
protein
antibodi
captur
test
individu
mous
sera
well
pool
sera
presenc
total
igg
specif
niv
g
rabv
g
test
antiniv
g
humor
respons
produc
solubl
niv
g
snivg
describ
snivg
dilut
coat
buffer
mm
na
co
ph
concentr
ngml
plate
elisa
maxisorp
plate
nunc
well
rabvg
also
resuspend
coat
buffer
concentr
ngml
plate
elisa
maxisorp
plate
nunc
per
well
overnight
incub
plate
wash
three
time
pbst
tween
pb
incub
h
room
temperatur
block
buffer
dri
milk
powder
pbst
volum
per
well
plate
wash
three
time
pbst
incub
overnight
serial
dilut
sera
immun
mice
pb
contain
bsa
plate
wash
time
next
day
follow
addit
horseradish
peroxidaseconjug
goat
antimouseigg
h
l
secondari
antibodi
jackson
immunoresearch
incub
h
room
temperatur
plate
wash
time
pbst
ophenylenediamin
dihydrochlorid
opd
substrat
sigma
ad
well
reaction
stop
addit
h
per
well
min
optic
densiti
determin
nm
od
fluoresc
reduct
neutral
assay
use
determin
highest
serum
dilut
would
reduc
infect
viru
assay
minor
modif
describ
walpita
et
al
ref
briefli
vero
cell
seed
cellswel
day
prior
experi
serum
sampl
heat
inactiv
min
serial
dilut
serumfre
dmem
incub
dilut
sampl
mix
pfu
niv
incub
h
serumviru
mixtur
ad
cell
monolay
incub
co
h
fix
nbf
h
immunofluoresc
assay
ifa
perform
permeabil
cell
triton
pb
min
block
bsa
min
stain
niv
g
proteinspecif
rabbit
polyclon
antiserum
produc
thermofish
scientif
niv
gp
freestyl
tetnivsg
gift
dr
christoph
c
broder
uniform
servic
univers
bsa
dilut
min
final
step
ifa
goat
antirabbit
igg
h
l
secondari
antibodi
alexa
conjug
life
technolog
hoechst
nucleic
acid
stain
thermofish
scientif
appli
cell
min
room
temperatur
dilut
cell
wash
pb
step
except
blockingprimari
antibodi
step
percentag
cell
infect
niv
detect
use
high
content
imag
system
operetta
perkinelm
inform
experiment
design
avail
natur
research
report
summari
link
articl
fig
vaccineinduc
neutral
titer
vitro
sera
mice
immun
studi
n
per
group
analyz
fluoresc
reduct
neutral
assay
one
valu
per
anim
yaxi
give
antibodi
dilut
requir
reduc
infect
niv
g
hev
g
rabbit
polyclon
antisera
use
posit
control
gray
bar
statist
signific
group
perform
use
ordinari
oneway
anova
follow
uncorrect
fisher
lsd
test
compar
immun
group
nonparametr
kruskalw
test
follow
uncorrect
dunn
multipl
comparison
test
use
compar
statist
signific
base
gender
p
p
p
p
